REGENXBIO Inc. (RGNX) has made remarkable progress in being able to advance its pipeline with various types of gene therapies. The last time I wrote about this article it was in a Seeking Alpha ...

Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular dystrophy at the front of the line. The company is positioning the program ...

Sarepta Therapeutics SRPT posted third-quarter 2024 adjusted earnings per share (EPS) of 62 cents, which beat the Zacks Consensus Estimate of a loss of 15 cents. Earnings rose 99% year over year, ...